MiR-125 is a highly conserved microRNA throughout many different species from nematode to humans. In humans, there are three homologs (hsa-miR-125b-1, hsa-miR-125b-2 and hsa-miR-125a). Here we review a recent research on the role of miR-125 in normal and malignant hematopoietic cells. Its high expression in hematopoietic stem cells (HSCs) enhances self-renewal and survival. Its expression in specific subtypes of myeloid and lymphoid leukemias provides resistance to apoptosis and blocks further differentiation. A direct oncogenic role in the hematopoietic system has recently been demonstrated by several mouse models. Targets of miR-125b include key proteins regulating apoptosis, innate immunity, inflammation and hematopoietic differentiation.
MicroRNAs (miRNAs) are 21-23-nucleotide non-coding RNAs that have crucial roles in fundamental biological processes by regulating the levels of multiple proteins. They are transcribed as primary miRNAs and processed in the nucleus by the RNase III endonuclease DROSHA to liberate 70-nucleotide stem loops, the precursor miRNA. The precursor miRNAs are then exported from the nucleus to the cytoplasm by Exportin 5/RanGTP, where further cleavage by the second RNase III enzyme DICER releases the mature miRNAs. [1] [2] [3] MiRNAs bind mainly to the 3 0 untranslated region of mRNAs by direct base-pairing to the 5 0 miRNA seed region, resulting either in repression of gene translation 1 or induction of mRNA degradation. 2 Recent data reveals, however, that miRNA regulation entails a far more complex posttranscriptional control than initially anticipated. 3 Many miRNAs are genomically organized as clusters and are cotranscribed from a single promoter as a single polycistronic transcript, although inconsistent expression of members can be detected in some miRNA clusters. 4, 5 Here, we review the role of miR-125 in normal and malignant hematopoiesis. MiR-125, a highly conserved miRNA transcribed from three different clusters, has recently emerged as a key regulator of HSCs. It has been shown to be dysregulated in multiple malignancies and to affect cell survival, differentiation and proliferation through the suppression of multiple targets. These fascinating recent discoveries raise many questions regarding its regulation, interactions with additional co-transcribed miRNAs and mechanisms of activity.
GENOMIC ORGANIZATION OF THE MIR-125B CLUSTER
MiR-125b is highly conserved among mammals, vertebrates and nematodes. Although the nomenclature sometimes differ (for example cel-lin-4 in Caenorhabditis elegans), the seed region is the same throughout all species containing miR-125b ( Figure 1a) . In viral genomes, there is a maximum concordance of only six nucleotides with the seed region of miR-125b (ebv-miR-BART21-5p, ebv-miR-BART8 and rlcv-miR-rL1-25). In humans, as in most of the genomes, there are two paralogs (hsa-miR-125b-1 on chromosome 11 and hsa-miR-125b-2 on chromosome 21), coding for the same mature sequence. There is no obvious correlation between the number of paralogs and the complexity of the genome, as the genome of the zebrafish (Danio rerio) contains three paralogs of miR-125b, whereas there is only one copy in chimpanzees (Pan paniscus), pufferfish (Tetraodon nigroviridis) or worms (Schistosoma japonicum, Schmidtea mediterranea).
In addition to paralogs that code for the same mature sequence, there are homologs that code for different mature sequences, which contain the same seed region and therefore might have similar functions. In the human genome, the homolog miR-125a is encoded on chromosome 19. In some other species (Danio rerio), there are three homologs encoded on different chromosomes (miR-125a, -125b and -125c), all sharing the same seed region (Figure 1a) . Interestingly, miR-351, which is encoded only in the mouse and rat genome, has the same seed region as miR-125b.
In humans, miR-125b-2 is organized in a cluster with miR-99a and let-7c. Hsa-miR-125b-2 is encoded B50 kb downstream of hsa-miR-99a and hsa-let-7c, which are located about 650 bp from each other. Although the distance of 50 kb is greater than the standard distance for a cluster, analysis of various genomes shows that this region is highly conserved in its organization, and therefore this region is considered to be a cluster. A second cluster (on chromosome 11 in humans) contains the paralog miR-125b-1 with let-7a-2 and miR-100, which both differ in only one nucleotide outside of the seed region of their family members, let-7c and miR-99a, respectively. The genomic organization of this second cluster is similar to that of the first. A third cluster (on chromosome 19 in humans) contains miR-99b, let-7e and miR-125a. Here, all three miRNAs are encoded close to each other (o1 kb).
This composition suggests that the cluster containing miR-125a probably has only one promoter and is transcribed as one transcript, whereas the cluster containing miR-125b may contain an alternative promoter, making it possible to transcribe miR-125b solely (Figure 1b) . [6] [7] [8] [9] This hypothesis is supported by recent research predicting miRNA promoters by combining bioinformatic analysis of nearby upstream DNA regulatory elements (transcription start sites (TSS), conserved transcription factor-binding sites, TATA boxes, A/B boxes) and epigenetic modifications (CpG islands, histone modifications, nucleosome positioning patterns) with chromatin immunopreciptiation screens or reporter assays. [6] [7] [8] [9] [10] [11] It seems that about half of the miRNAs located in introns of protein-coding genes (B60%) contain putative promoters regulating transcription independent of their host gene. 7 This is also supported by the observed discrepancy in expression of several miRNAs and their host genes. 12, 13 Ozsolak et al. 8 showed that intronic miRNAs having independent transcription initiation regions had the shortest TSS-to-miRNA distance with a mean distance of 4.2±3.5 kb. These miRNAs were located significantly farther (mean distance of 57 kb) from their host gene TSSs in comparison with intronic miRNAs utilizing host gene TSSs. These results suggest that certain intronic miRNAs located far away from their host TSSs may have evolved to adopt nearby independent novel TSSs in order to make the transcription of primary miRNA faster and more efficient. 8 These issues on how the regulation of miRNAs expression is dependent on their genomic localization are highly relevant for the miR-125b clusters. Whereas most of the studies agree on hsa-miR-99a, hsa-let-7c and hsa-miR-125b-2 being intragenic (host gene LINC00478, chr 21: 17.442.842-17.982.094; NC_000021.8, NCBI build 37.2) and hsa-miR-100, hsa-let-7a-2, hsa-miR-125b-1, hsa-miR-99b, hsa-let-7e and hsa-miR-125a being intergenic, Corcoran et al. 6 claim that hsa-miR-100 and hsa-let-7a-2 are also intragenic (host gene, non-protein coding, chr 11: 121.959.811-122.073.770; NC_000011.9, AK091713). Several independent putative promoters have been described (Figure 1b) . One that drives co-expression of hsa-miR-100 and hsa-let-7a-2 independent of their potential host gene, [6] [7] [8] [9] one that drives co-expression of hsa-miR-99a and hsa-let-7c independent of their host gene, [6] [7] [8] [9] 11 and another that drives co-expression of hsa-miR-99b, hsa-let-7c and hsa-miR-125a.
6-9 Hsa-miR-125b-1 (refs 6,7,9) and hsa-miR-125b-2 (refs 6,8) are predicted to be expressed from an independent promoter. In summary, all three human homologs of miR-125 are involved in a cluster containing members of the miR-99 and let-7 family. The genomic organization of these three clusters is highly conserved as well as the seed regions of the different paralogs and orthologs. This underscores the hypothesis that these three miRNA families are partly co-regulated and have cooperative biological functions.
REGULATORS OF MIR-125B EXPRESSION
Relatively little is known about the regulation of miR-125b expression. The regulatory sequences (promoter, enhancer) of
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miR-125b and its associated miRNAs located in its cluster have not yet been fully characterized. Contradictory data exists regarding the regulation of miR-125b. It has been shown to be induced by CDX2, 14 induced or repressed by nuclear factor kappa beta (NF-kb) [15] [16] [17] and P53, 18, 19 and to be repressed by myelocytomatosis viral oncogene homolog (MYC) 20 and AKT1. 21 It has been suggested that miR-125b is directly regulated by androgens. In prostate cancer cells, androgen stimulation was shown to induce an enhanced abundance of miR-125b in an androgen receptor-dependent manner. It was observed that the androgen receptor was recruited to the 5'DNA region of miR125b-2 in the presence of R1881 (synthetic androgen). This stimulation was androgen-specific, as estradiol did not induce this effect. 22 The upregulation of miR-125b was shown to be associated with the reduction of BCL2-antagonist/killer (BAK1), P53 and PUMA levels, all of which are known targets of miR-125b. 22, 23 This is further supported by the fact that lowering miR-125b expression by androgen withdrawal was associated with an increase in BAK1, P53 and PUMA expression. 23 
MIR-125B IN HEMATOPOIESIS
The ability of a single hematopoietic stem cell (HSC) to reconstitute the entire blood system for the lifetime of an organism is made possible by the balance of factors that regulate self-renewal and fate-commitment decisions. The expression pattern of miR-125b suggests that it has a specialized role in regulating hematopoiesis at the stem-cell level. Analysis of miRNA expression profiles in multiple hematopoietic subpopulations demonstrated that one of the most expressed miRNAs in HSCs, compared with all other progenitor populations, is miR-125b (Bsevenfold more than total bone marrow (BM)). 24, 25 Further analysis of lineage-negative cells revealed that miR-125b is one of the miRNAs that was specifically enriched in the long-term HSC population. 24 Whereas the levels of miR-125b drop significantly in committed progenitors, the levels in common lymphoid progenitors are higher than in common myeloid progenitors. 25 HSCs transduced with miR-125b demonstrate an improved engraftment and increased self-renewal as shown by serial transplantation experiments. [24] [25] [26] Importantly, miR-125b was shown to affect mainly long-term multilineage engraftment, being consistent with a putative function of regulating stem-cell homeostasis. 24, 26 There are contradictory findings regarding the lineage that is expanded because of the overexpression of miR125b. Ooi et al. 25 demonstrated preferential expansion of the lymphoid lineage whereas other studies demonstrated a preferential expansion of the myeloid lineage. 24 Contrasting results from different studies might be related to the varying levels of miR-125b achieved during transduction experiments. Indeed, a major limitation of these studies is that all of them are overexpression experiments performed in cells already expressing relatively high levels of endogenous miR-125b.
Expression of miR-125b results not only in the expansion of both myeloid 24, [26] [27] [28] and lymphoid 25, 26 progenitors but also in differentiation arrest. [29] [30] [31] [32] High expression of miR-125b is observed in germinal center (GC) centroblasts during human B-lineage differentiation. It is suggested that miR-125b is an inhibitor of premature plasma cell (PC) differentiation, as it targets the transcription factors B-lymphocyte-induced maturation protein-1 (BLIMP-1) and interferon regulatory protein-4 (IRF-4) 30,31 ( Figure 2 ). It may also regulate T-lymphoid differentiation as it has recently been demonstrated to be expressed in human naïve T-cells and to target several T-cell differentiation genes. 32 In 32D mouse myeloid cells, miR-125b was shown to be induced by granulocyte colony-stimulating factor and to negatively regulate granulocyte colony-stimulating factor signaling. 27 Therefore, the block in myeloid differentiation 29 caused by miR-125b may be the result of a negative feedback loop in the granulocyte colony-stimulating factor pathway. This interesting model awaits confirmation in primary cells. MiR-125b is also involved in inflammation and innate immunity. In a recent publication by Chaudhuri et al., 33 miR-125b was found to be enriched in macrophage cells and to enhance their activity including antigen presentation, T-cell activation and antitumorigenic potential. Targeting IRF-4, a negative regulator of macrophage proinflammatory pathways, was suggested to be the mechanism for these phenotypes. 33 In B-lymphocytes and macrophages, signals originating in response to the Gram-negative product Lipopolysaccharides (LPS) trigger Toll-like receptor 4 and activate NF-kb. NF-kb induces the expression of several proinflammatory cytokines, including tumor necrosis factor a, which is involved in pathogen clearance ( Figure 3) .
MiR-125b acts as a negative regulator of this pathway by reducing the levels of its target tumor necrosis factora 15, 34 and, unusual for miRNAs, by enhancing the stability of the NF-kb inhibitor NKIRAS2 (KBRAS2) 35 ( Figure 3) . Enhancement of the stability of a target gene transcript was described in several recent publications. 15, 36 One of the suggested mechanisms for the enhanced stability of a transcript is the binding of an miRNA with the AU-rich elements of an mRNA. This interaction, mediated through the FXR1-AGO2 complex, results in enhancement of translation of the target gene. 37 Interestingly, NF-kb can either repress or activate pri-miR-125b transcription depending on the cell type and on the amount of time after encountering the pathogen, thereby either further enhancing or suppressing the inflammatory response. [15] [16] [17] 35 Hence, miR-125b has been suggested to have a remarkably diverse role in the hematopoietic system. It enhances survival and proliferation of some early hematopoietic progenitors and blocks their terminal differentiation. It is also involved in inflammation by regulation of the NF-kb pathway and by promotion of differentiation and activation of macrophages.
However, we suggest evaluating these results with extra caution as most of this data is based on overexpression experiments. The true and non-redundant functions of this miRNA in the biology of hematopoietic cells will be determined only by future loss-offunction studies.
MIR-125B IN HEMATOPOIETIC MALIGNANCIES
Leukemias and other hematopoietic neoplasms are often caused by somatic aberrations in hematopoietic developmental genes. 38 Given its expression pattern and the putative role of miR-125b in HSCs, it is reasonable to hypothesize that dysregulation of its expression may be associated with hematopoietic malignancies. Indeed, such a dysregulation has recently been described in the myeloid and lymphoid malignancies and a direct role as a hematopoietic oncomiR has been experimentally demonstrated.
MIR-125B IN MYELOID MALIGNANCIES
A direct role for miR-125b in acute myeloid leukemia (AML) and in myelodysplastic syndrome is thought to exist owing to the involvement of miR-125b in the rare recurrent chromosomal translocation t(2;11)(p21;q23), leading to an overexpression (up to 90-fold) of the miRNA in comparison with normal BM. 29 Overexpression of miR-125b was shown to cause myeloid differentiation arrest in human CD34 þ cells, 28, 29 in several leukemic cell lines and in 32D cells treated with granulocyte colony-stimulating factor. 27 Increased expression of miR-125b has been observed in a variety of myeloid malignancies. The expression levels varied depending on the methodologies used for expression and controls, but are generally up to 20-fold compared with normal BM. These malignancies include myelodysplastic syndrome involving the del (5q), 39, 40 AMLs harboring the AML1/ETO translocation, 41 AMLs associated with the FLT3 mutation, 41 a few cases of chronic myelogenous leukemia, myeoproliferative neoplasms 42 and acute promyelocytic leukemia 43, 44 (Table 1 ). The most investigated hematopoietic malignancy with increased expression of miR-125b is acute megakaryocytic leukemia associated with Down's syndrome (DS). Klusmann et al. 28 showed that knockdown of miR-125b in AMKL cell lines decreased their proliferation. Ectopic expression of the miRNA in murine and human progenitors enhanced the size and number of megakaryocyte and megakaryocytic erythroid progenitor colonies. Consistent with the putative role of miR-125b in HSC self-renewal, MKs and MEPs transduced with miR-125b-2 displayed a proliferative advantage and the ability for self-renewal as shown by serial replating assays. Interestingly, unlike the granulocytic and monocytic differentiation arrest observed in myeloid progenitors, [27] [28] [29] impairment of differentiation of megakaryocyte transduced with miR-125b was not observed. 28 Finally, miR-125b was shown to collaborate with mutated GATA1, typically expressed in DS acute megakaryocytic leukemia, in the transformation of murine megakaryocytic progenitors. 28 Together, these observations suggest a major pro-proliferative role for miR125b in AMKL.
MIR-125B IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Similar to AMLs, the observation suggesting a direct role for miR-125b in ALL is its upregulation caused by the insertion of miR125b-1 into the Immunoglobulin heavy chain locus (IgH) enhancer locus in ALLs harboring the translocation t(11;14)(q24;q32) 42, [45] [46] [47] ( Table 1) .
We observed that increased expression of miR-125b, together with miR-99a and let-7c from the cluster on chromosome 21 (up to 20-fold overexpression compared with other ALLs), is specifically associated with TEL-AML1 (ETV6-RUNX1) ALL, the most common childhood ALL 48 (Table 1 ). This has recently been confirmed by Schotte et al. 49 Our original hypothesis was that the miRNA cluster encoded on chromosome 21 would be overexpressed in DS and in hyperdiploid ALL, two conditions having additional copies of chromosome 21. To our surprise, overexpression was observed only in the control group TEL-AML1 ALL that had a structural aberration of chromosome 21. The basis for the association between this fusion translocation and overexpression of the miR-125b cluster is unclear as miR-125b does not seem to be regulated by the TEL-AML1 fusion.
Overexpression studies in lymphoid progenitors and knockdown studies in the REH leukemia cell line (TEL-AML1-positive) demonstrated that miR-125b provides a survival advantage in the presence of various pro-apoptotic stimuli in a P53-independent manner. This anti-apoptotic function was also demonstrated for primary TEL-AML1 ALL cells treated with vincristine 49 and in Jurkat T-ALL cells or primary mouse lymphoid progenitors transduced with miR-125b. 25 As TEL-AML1 and miR-125b expression appear as independent events, it is tempting to speculate that they may cooperate in the leukemogenic process. 48 A similar increased expression of miR-125b was also described in BCR-ABL ALL and Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CML, chronic myeloid leukemia; DS-AMKL, Down's syndrome acute megakaryocytic leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; TC, translocation/cyclin. cooperation between the miRNA and BCR-ABL has been shown in vivo 26, 42 (Table 1) .
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MIR-125B CAUSES AML AND ALL IN MOUSE MODELS
Two transplantation models of murine leukemias caused by miR125b were recently described. In one study, mice were reconstituted with BM progenitors transduced with three different expression levels of miR-125b. 24 Two months after reconstitution, all mice expressing miR-125b, regardless of the construct used, had a subtle elevation in total white blood cell counts. Mice reconstituted with BM expressing high levels of miR-125b exhibited a clear myeloproliferative neoplasm that was characterized by an increased absolute number of monocytes and neutrophils, and decreased levels of lymphocytes, red blood cells and platelets. These mice transformed to fatal AML. Interestingly, transplantations with cells expressing the lowest levels of miR-125b were associated with an increase in lymphoid cells, similar to the observations reported by Ooi et al. 25 In another transplantation model, transduction of lineage-negative fetal liver hematopoietic cells with a retrovirus-expressing miR-125b (700-fold overexpression) lead to fatal hematopoietic malignancies consisting of myeloproliferative neoplasms, B-and T-ALL. 26 To examine whether overexpression of miR-125b is the cause of ALL in cases having the translocation t(11;14)(q24;q32), transgenic mice expressing miR-125b under the immunoglobulin enhancer (Em/miR-125b-TG mice) were recently generated. These mice developed B-cell clonal lymphoid leukemias resistant to apoptosis, similar to the human leukemias. 42 Together, the observations in human leukemias and in mouse models demonstrate that miR-125b (both miR-125b-1 and miR125b-2) is a leukemogenic oncomiR.
MIR-125B IN MULTIPLE MYELOMA (MM)
MM is a malignant proliferation of BM PCs, characterized by a profound genomic instability involving both numerical and structural chromosomal aberrations with potential prognostic relevance. A few cases of MM were found to express miR-125b-2, in particular the translocation/cyclin classification #5, involving either the t(14;16)(q32;q23) or t(14;20)(q32;q11) translocations (up to 14-fold upregulation) 50, 51 (Table 1) . Interestingly, similar to ALL, miR-125b-2 is not overexpressed in MM with trisomy 21.
Not much is known about the function of miR-125b in MM, except the suggested inactivation of P53. 52 On the contrary, the U266 MM cell line transduced with miR-125b exhibited an exaggerated death rate compared with control cells by downregulation of its targets BLIMP-1 and IRF-4. The introduction of miR-125b also led to the reduced expression of SYNDECAN-1 (CD138), a cell surface molecule expressed by myeloma and primary PCs. 30 Hence, it is unclear whether miR125b has an oncogenic role in MM. As MM is an extremely heterogeneous malignancy, the role of miR-125b needs to be further examined in the specific subtypes of MM in which it is overexpressed.
MIR-125B AND TRISOMY 21
As miR-125b-2 is located on chromosome 21, it is reasonable to hypothesize that it could be upregulated in DS or in leukemias with somatic polysomy of chromosome 21. Indeed, upregulation of all five miRNAs encoded on chromosome 21 was detected in the brain and hearts of fetuses with DS. 53, 54 However, the association between germline or somatic trisomy 21 and the expression of miR-125b-2 in leukemias is not straightforward. MiR125b-2 is overexpressed in the myeloid leukemias 28, 55 but not in the lymphoid leukemias associated with DS. 48 Moreover, it is hardly expressed in ALL or myelomas with somatic trisomy 21. 48, 50, 51 Thus, there is no correlation between the expression of miR-125b and its genomic copy.
TARGETS AND PATHWAYS REGULATING CELL SURVIVAL, PROLIFERATION AND DIFFERENTIATION
One of the greatest challenges in miRNA research is the identification and functional analysis of their targets. These challenges stem from (a) the poor predictability of targets based on sequence alignment to 3 0 untranslated regions; (b) the magnitude of change in RNA and protein levels of the target, a change that is, in the case of proteins, often below the sensitivity of current routine protein analysis methodologies and (c) the multiplicity of targets affected by each miRNA. Indeed, as miRNAs are thought to affect the expression of multiple proteins, it is difficult to calculate and model the network effects of these perturbations.
With these important caveats in mind, several putative targets of miR-125b regulating cell survival, proliferation and differentiation have been suggested and experimentally confirmed ( Table 2) .
The P53 protein regulates multiple cellular pathways in response to stress, in particular in response to genotoxic stress. Le et al. 56 showed that miR-125b downregulates the expression of P53 and its targets in zebrafish and human cells. However, in mice, where the binding site is not conserved, P53 was not found to be targeted by miR-125b. 48 In addition, it was suggested that miR125b targets five additional genes that are upstream regulators of P53: PPP1CA, PPP2CA, PRKRA, PLK3 and PLAGL1.
56,57 These findings were not confirmed in human leukemia cells (REH) with endogenous expression of miR-125b, 48 and therefore the antiapoptotic effects of miR-125b in these cells are P53 independent. Whether or not P53 is a bona-fide target in all cell types and species, miR-125b was demonstrated to target other components of the P53 pro-apoptotic network, including BAK1, PUMA, BMF, TRP53INP1 and Kruppel-like factor 13 (KLF13). 22, 23, 25, 27, 42, [56] [57] [58] [59] All were shown to be direct targets of miR-125b in more than one system and cell type (Figure 4) .
Inhibition of the three targets, DICER1, ST18 (ref. 28) and SUV39H1 (ref. 60) was suggested to be associated with the proproliferation phenotype endowed by the overexpression of miR-125b. Small hairpin RNAs directed against DICER1 or ST18 in human CD34 þ hematopoietic stem and progenitor cells (HSPCs) increased the number of CFUs by 1.4-fold. 28 The possibility that DICER, a key protein in miRNA physiology, may be a target of miR-125b is intriguing, as it would suggest that some of the effects observed by miR-125b expression might be because of the inhibition of other miRNAs. 
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Another mechanism, through which miR-125b may exert its pro-proliferative effect on hematopoietic cells, is by targeting the histone methyltransferase SUV39H1. 60 The downregulation of SUV39H1 by miR-125b, in two different non-hematopoietic systems, led to derepression of key inflammatory chemokines and cytokine genes such as interleukin (IL)-6 and monocyte chemoattractant protein-1 (MCP-1), by the decrease of the repressive H3K9me3 chromatin mark at their promoter regions. 60 IL-6 is a major cytokine-driving hematopoietic cell proliferation, as shown in MM in which miR-125b is sometimes overexpressed.
MiR-125b was demonstrated to inhibit cell differentiation of granulocytes and monocytes in the myeloid lineage [27] [28] [29] and of PCs 30, 31 and naïve T-cells 32 in the lymphoid lineage. MiR-125b, one of the signature miRNAs of naïve CD4 þ T-cells, was found to regulate a network of gene-encoding molecules involved in T-cell differentiation into effector cells, including IFNG, IL2RB, IL10RA and PRDM1. 32 The inhibition of B-cell differentiation into mature PCs is thought to be caused by the inhibition of BLIMP-1 and IRF-4.
30,31
Although not directly demonstrated, it was suggested that BCL-6 mediates the overexpression of miR-125b in GC B-cells through the repression of C-MYC. C-MYC has a consensus binding site 12 kb upstream of human miR-125b and was shown to downregulate miR-125b. 20, 30 It has been suggested that miR-125b facilitates BCL-6 maintenance of the GC phenotype by inhibiting BLIMP-1 and IRF-4 expression (essential for PC differentiation) and by creating a feed forward regulation of (Figure 2 ).
THE ROLE OF THE CLUSTER MIR-125B-2, MIR-99A AND LET-7C IN LEUKEMIA/HEMATOPOIESIS
As described earlier, miR-125b-2 resides in a cluster together with let-7c and miR-99a on chromosome 21 (Figure 1b) . Few reports have studied the cluster as one functional unit. They indicate a common regulation of the cluster members in different types of hematopoietic malignancies. However, nothing is known on the added function of the other cluster members.
Expression of all members of the cluster was demonstrated in naïve T-cells, 32 B-cell precursor (BCP)-ALL, 48 myelodysplastic syndrome 39 and myeloma. 50,51 C-MYC was found to regulate the cluster as one functional unit. 20 However, only let-7c and miR125b were found to be upregulated in response to androgens. 22 Although the expression of let-7c varies, miR-125b is almost always co-expressed with miR-99a. This correlation was observed in early hematopoietic progenitors. MiR-99a demonstrates an expression profile similar to miR-125b, with highest expression levels in HSCs and gradually decreasing levels as the progenitors differentiate. Moreover, miR-99a also demonstrates higher expression levels in common lymphoid progenitors compared with common myeloid progenitors. 25 These results suggest that the miR-125b-2 polycistron may be regulated by posttranscriptional mechanisms in early hematopoiesis. Similar to miR-125b-2, miR-99a was found to be upregulated in AMKL cell lines, 61 in AMLs with the translocation AML1/ETO, 41 in APL involving PML/RARA 44 and in resistant ALLs. 49 However, in more differentiated B-cells, a correlation in the expression level could not be demonstrated between miR-125b-2 and miR-99a or let-7c. An increased expression of miR-125b was found in GC centroblasts during human B-lineage differentiation, whereas miR-99a and let-7c were overexpressed in macrophages and T-cells, respectively. 30 Although not much is known about the added function of the whole cluster, beyond the activity of miR-125b, in hematopoietic malignancies and in normal hematopoiesis, coordinated regulation of miR-125b and let-7a (a let-7 family member) in inflammation was demonstrated. 16, 17, 35, 60, 62 For example, activation of macrophage cells with LPS mediated the repression of miR-125b levels and the induction of let-7a expression. This coordinated regulation resulted in the activation of NF-kb and induction of the inflammatory response.
MIR-125A
MiR-125a, which shares the same seed region as miR-125b (Figure 1 ), was also demonstrated to have a similar expression pattern. Indeed, miR-125a is enriched in HSCs (up to 23-fold over total BM), particularly in long-term HSCs (up to 6-fold) 24, 63, 64 and downregulated upon differentiation. 64 MiR-125a was demonstrated to have a role in HSCs, increasing their number in vivo and in vitro, 63, 64 and causing a myeloproliferative phenotype upon transplantation. 64 Whereas Guo et al. 63 showed amplification of the HSC pool upon sustained miR-125a overexpression, Gerrits et al. 64 reported a decline of the primitive BM compartment and loss of competitive advantage upon secondary transplantation.
These phenotypes could be explained by the reduction of apoptosis in the immature hematopoietic progenitors, possibly through targeting pro-apoptotic genes. BAK1 was demonstrated to be directly targeted by miR-125a. 63, 64 The similarity to miR-125b is not restricted to the stem cell population, as miR-125a and its cluster members, miR-99b and let7e were found to be preferentially expressed by the centroblasts in the GC. However, as opposed to miR-125b, miR-125a was not able to negatively regulate the 3'untranslated region of BLIMP-1 and IRF-4.
30
Notwithstanding the similar function, the expression of miR125a does not always correlate with miR-125b expression. MiR125a was found to have a role in activated T-cells, 65 as opposed to miR-125b in naïve T-cells. 32 This was accomplished by targeting the KLF13, which resulted in the reduction of RANTES levels, through a feedback loop. 65 Moreover, miR-125a and its cluster members were found to be expressed at a higher level in myeloma translocation/cyclin classification #4 involving the t(4;14)(p16.3;q32) translocation, which is a different MM classification subtype than miR-125b. 51 
MIR-125B IN SOLID TUMORS-ONCOMIR OR TUMOR SUPPRESSOR?
Dysregulation of miR-125b has been reported to occur in multiple human cancer types, including cancers of the stomach, 66 Clinical prostate cancer samples were found to overexpress miR-125b. 76 Furthermore, enforced expression of miR125b promoted tumor growth through mediation of a broad attenuation of the intrinsic apoptosis pathway by targeting P53, PUMA and BAK1. 23 MiR-125b was also found to stimulate androgen-independent growth of prostate cancer cells in vitro. 22 High expression of miR-125b has also been observed in oligodendroglial gliomas. 72 Overexpression of miR-125b in human glioma cell lines promotes proliferation and inhibits apoptosis through targeting BMF 58 or through the reduction of P53 protein levels and targets (P21 and BAX).
56
In contrast, the upregulation of miR-125b expression specifically resulted in a proliferation defect in the CD133-positive glioma cells (a putative stem cell marker in normal and malignant brain tissues). 77 Consistent with this observation, in breast cancer, miR-125b might be a tumor suppressor. MiR-125b levels were demonstrated to decrease, as compared with normal breast tissue. Furthermore, miR-125b was found to suppress the oncoproteins MUC1, ERBB2 and ERBB3, inhibiting the growth of breast cancer cells and promoting their sensitivity to genotoxic anticancer agents. 73, 74 In contrast to these observations, miR-125b was found to be upregulated in Taxol-resistant cancer cells, with its overexpression inhibiting Taxol-induced cytotoxicity and apoptosis by targeting BAK1.
59
These findings collectively indicate that miR-125b has a pivotal role in many different cell types. Depending on cell context, miR125b-1 and miR-125b-2 contribute to oncogenesis or function as tumor suppressors.
FUTURE PERSPECTIVES
The functional analysis of the clusters of miR-125b-2 and 125b-1 is only one of the questions that require further research. A large body of recent research has suggested that miR-125b is a key regulator of normal and malignant hematopoiesis. However, in the absence of appropriate loss-of-function in vivo experiments, it is presently difficult to evaluate the role of miR-125b and its associated cluster in normal hematopoiesis. The in vivo overexpression mouse models and the presence of recurrent chromosomal translocations that cause direct activation of miR125b expression in human leukemias, confirm that miR-125b is an oncomiR in the hematopoietic system. However, the basis of its differential activity in different tissues as both tumor promoter and tumor suppressor is currently unknown. Similarly, little is known about how miR-125b functions and how it is regulated. These basic questions have translational perspectives. As miR-125b is a leukemia oncogene it could serve as a therapeutic target. Deciphering its mode of regulation and its critical downstream targets may lead to strategies that manipulate its upstream regulators or downstream targets. The relevance of these challenges goes beyond miR-125b, as they are a fundamental part of current miRNA research. Research of miR-125b can lead the way.
